InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
ICP-B208 is InnoCare's second ADC from its in-house platform to enter clinical development. There are no approved CDH17 targeted ADCs globally.
ICP-B208 is InnoCare's second ADC from its in-house platform to enter clinical development. There are no approved CDH17 targeted ADCs globally.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.